ATE229513T1 - Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen - Google Patents
Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungenInfo
- Publication number
- ATE229513T1 ATE229513T1 AT98402155T AT98402155T ATE229513T1 AT E229513 T1 ATE229513 T1 AT E229513T1 AT 98402155 T AT98402155 T AT 98402155T AT 98402155 T AT98402155 T AT 98402155T AT E229513 T1 ATE229513 T1 AT E229513T1
- Authority
- AT
- Austria
- Prior art keywords
- hexahydro
- napht
- oxazine
- production
- pharmaceutical compositions
- Prior art date
Links
- DNUJVGBNIXGTHC-UHFFFAOYSA-N 3,6-dihydro-2h-oxazine Chemical compound C1NOCC=C1 DNUJVGBNIXGTHC-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9710852A FR2767825A1 (fr) | 1997-09-01 | 1997-09-01 | Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE229513T1 true ATE229513T1 (de) | 2002-12-15 |
Family
ID=9510643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98402155T ATE229513T1 (de) | 1997-09-01 | 1998-09-01 | Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6025356A (enExample) |
| EP (1) | EP0899267B1 (enExample) |
| JP (1) | JP4417451B2 (enExample) |
| CN (1) | CN1088064C (enExample) |
| AT (1) | ATE229513T1 (enExample) |
| AU (1) | AU740928C (enExample) |
| BR (1) | BR9803933A (enExample) |
| CA (1) | CA2246482C (enExample) |
| DE (1) | DE69810034T2 (enExample) |
| DK (1) | DK0899267T3 (enExample) |
| ES (1) | ES2189108T3 (enExample) |
| FR (1) | FR2767825A1 (enExample) |
| HU (1) | HU226059B1 (enExample) |
| NO (1) | NO311218B1 (enExample) |
| NZ (1) | NZ331637A (enExample) |
| PL (1) | PL194533B1 (enExample) |
| PT (1) | PT899267E (enExample) |
| ZA (1) | ZA987963B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| CA2496452A1 (en) * | 2002-08-30 | 2004-03-11 | Biostratum, Inc. | Inhibitors of post-amadori advanced glycation end products |
| EP1620083A2 (en) * | 2003-04-18 | 2006-02-01 | Pharmacia & Upjohn Company LLC | Combination therapies |
| FR2906249B1 (fr) * | 2006-09-26 | 2008-12-19 | Servier Lab | Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2098511A1 (en) | 2008-03-07 | 2009-09-09 | Solvias AG | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring |
| WO2009156458A1 (en) * | 2008-06-27 | 2009-12-30 | H. Lundbeck A/S | Novel phenolic and catecholic amines and prodrugs thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4420480A (en) * | 1981-11-20 | 1983-12-13 | Merck & Co., Inc. | Hexahydronaphth[1,2-b]-1,4-oxazines |
| CA1204745A (en) * | 1981-11-20 | 1986-05-20 | Merck Co. | Hexahydronaphth (1,2-b) -1,4 -oxazines |
| US4540691A (en) * | 1984-04-13 | 1985-09-10 | Nelson Research & Development Co. | Dopamine agonists and use thereof |
| US5486611A (en) * | 1989-07-13 | 1996-01-23 | The Upjohn Company | Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives |
| WO1991019719A1 (en) * | 1990-06-15 | 1991-12-26 | Whitby Research, Inc. | Substituted naphthoxazines useful as dopaminergics |
-
1997
- 1997-09-01 FR FR9710852A patent/FR2767825A1/fr active Pending
-
1998
- 1998-08-31 NO NO19984007A patent/NO311218B1/no not_active IP Right Cessation
- 1998-08-31 BR BR9803933-4A patent/BR9803933A/pt not_active Application Discontinuation
- 1998-08-31 NZ NZ331637A patent/NZ331637A/xx not_active IP Right Cessation
- 1998-08-31 CA CA002246482A patent/CA2246482C/fr not_active Expired - Fee Related
- 1998-08-31 PL PL328285A patent/PL194533B1/pl not_active IP Right Cessation
- 1998-08-31 CN CN98119987A patent/CN1088064C/zh not_active Expired - Fee Related
- 1998-08-31 HU HU9801951A patent/HU226059B1/hu not_active IP Right Cessation
- 1998-08-31 US US09/144,025 patent/US6025356A/en not_active Expired - Lifetime
- 1998-09-01 AT AT98402155T patent/ATE229513T1/de active
- 1998-09-01 DK DK98402155T patent/DK0899267T3/da active
- 1998-09-01 PT PT98402155T patent/PT899267E/pt unknown
- 1998-09-01 DE DE69810034T patent/DE69810034T2/de not_active Expired - Lifetime
- 1998-09-01 JP JP24691098A patent/JP4417451B2/ja not_active Expired - Fee Related
- 1998-09-01 ES ES98402155T patent/ES2189108T3/es not_active Expired - Lifetime
- 1998-09-01 AU AU83024/98A patent/AU740928C/en not_active Ceased
- 1998-09-01 ZA ZA987963A patent/ZA987963B/xx unknown
- 1998-09-01 EP EP98402155A patent/EP0899267B1/fr not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9801951A2 (hu) | 2000-02-28 |
| EP0899267A1 (fr) | 1999-03-03 |
| CN1222516A (zh) | 1999-07-14 |
| US6025356A (en) | 2000-02-15 |
| AU740928C (en) | 2002-05-16 |
| NO984007L (no) | 1999-03-02 |
| JPH11130759A (ja) | 1999-05-18 |
| HUP9801951A3 (en) | 2000-04-28 |
| NO984007D0 (no) | 1998-08-31 |
| NO311218B1 (no) | 2001-10-29 |
| DE69810034T2 (de) | 2003-08-14 |
| CA2246482C (fr) | 2002-11-26 |
| HU226059B1 (en) | 2008-04-28 |
| CN1088064C (zh) | 2002-07-24 |
| CA2246482A1 (fr) | 1999-03-01 |
| DK0899267T3 (da) | 2003-03-10 |
| AU740928B2 (en) | 2001-11-15 |
| PL194533B1 (pl) | 2007-06-29 |
| PT899267E (pt) | 2003-04-30 |
| HK1020340A1 (en) | 2000-04-14 |
| AU8302498A (en) | 1999-03-11 |
| DE69810034D1 (de) | 2003-01-23 |
| BR9803933A (pt) | 2001-04-24 |
| PL328285A1 (en) | 1999-03-15 |
| EP0899267B1 (fr) | 2002-12-11 |
| ES2189108T3 (es) | 2003-07-01 |
| HU9801951D0 (en) | 1998-11-30 |
| JP4417451B2 (ja) | 2010-02-17 |
| NZ331637A (en) | 1999-07-29 |
| FR2767825A1 (fr) | 1999-02-26 |
| ZA987963B (en) | 1999-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69426331D1 (de) | Arzneimittel gegen nervöse erkrankungen | |
| AU2464997A (en) | New 3-(piperid-4-YL)-1,2-benzisoxazole and 3-piperazin-4-YL)-1,2-benzisoxazole compounds, processes for their preparation and pharmaceutical compositions containing them | |
| ATE204574T1 (de) | Piperazin-, piperidin- und 1,2,5,6- tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen | |
| PT97710A (pt) | Processo para a preparacao de novos derivados da amino-piperidina,da amino-pirrolidina e de amino-per-hidroazepina | |
| ATE229513T1 (de) | Disubstituierte trans-3,4,4a,5,6,10b-hexahydro-2h-napht(1,2-b)- ,4-oxazine, verfahren zu deren herstellung und diese enthaltende pharmazeutigsche zusammensetzungen | |
| DE59607208D1 (de) | Verwendung eines Natrium- oder Lysiniumsalzes von Crotonsäureamidderivaten zur Herstellung eines Arzneimittels zur Behandlung von Krebserkrankungen | |
| DE69603667D1 (de) | Indol-, Indazol- und Benzisoxazolderivate zur Behandlung von Schizophrenia | |
| ATE281452T1 (de) | 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| FI956016A0 (fi) | 1,2-silloitettujen 1,4-dihydropyridiinien käyttö lääkeaineina | |
| ATE198752T1 (de) | Tetrazyclisch 1,4-oxazinverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| ATE281453T1 (de) | 4-amino-2-ureido-pyrimidin-5-carbonsäureamide, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| ATE200780T1 (de) | Aminoalkyl benzothiazolinone, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0899267 Country of ref document: EP |